Navigation Links
VARICELLA-ZOSTER (VZ) IgG IFA TEST SYSTEM

ProductsVARICELLA-ZOSTER (VZ) IgG IFA TEST SYSTEM
Company Zeus Scientific, Inc.
Item VARICELLA-ZOSTER (VZ) IgG IFA TEST SYSTEM
Features 
  • Rapid & Specific
  • Qualitative & Semi-Quantitative Procedures
  • Choice of slide configurations (6, 8, 12, 16, 24, 96 wells)
  • Consistent product quality & availability
  • Conjugates & substrates optimized to reduce background staining - Easy to read
  • Stable substrates providing extended expiration dates
  • ZORBA IgG Removal Reagent® for use in performing IgM detection assays - reduces false negative & false positive reactions due to IgG and RF interference
  • Multiple tissue slides for simultaneous detection of multiple antibodies
Description Varicella-Zoster (VZ) test system is intended for the qualitative and semi-quantitative detection of VZ IgG antibody in human sera by the indirect fluorescent antibody (IFA) technique. The assay can determine or confirm a recent infection or immune status, and is for in vitro diagnostic use.
Info Zeus Scientific, Inc.
Customer Service: (800) 286-2111
Web site: http://www.zeussci.com

Related medicine products :

1. DUALSWITCH-SHUNTSYSTEM for L-P-Derivation
2. ISYSTEM-ABDv2™A/B Scan unit
3. ISYSTEM-ABD A/B-scan unit
4. SEDIPLAST ESR SYSTEM (without diluent)
5. SEDIPLAST ESR SYSTEM (with diluent)
6. ISYSTEM-ABDv2A/B Scan unit
7. The REFLEXION 1st MPJ IMPLANT SYSTEM
8. MEASLES (Rubeola) IgG ELISA TEST SYSTEM
9. MUMPS IgG ELISA TEST SYSTEM
10. SYSTEM ONE Orbital Illumination System
11. ALEXI® WOUND RETRACTOR SYSTEM
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Survivors of childhood cancer less likely to marry 10291 1Survivors of childhood cancer less likely to marry 10291 2HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 1HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 2HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 3Statewide Drug Card Program Launching 59108 1